BCM
BMRN icon

Barometer Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Barometer Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-31,590
Closed -$4.32M – 123
2015
Q2 		$4.32M Buy
31,590
+23,195
+276% +$2.87M 0.35% 57
2015
Q1 		$1.05M Buy
+8,395
New +$889K 0.08% 100

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Barometer Capital Management's BMRN Position: Q3 2015 in Review

Barometer Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 31,590 shares — an estimated $4.32M sold.

Barometer Capital Management first reported a position in BMRN in Q1 2015 and held it in 2 quarters. The position peaked at $4.32M in Q2 2015. 393 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

  • Barometer Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Barometer Capital Management sold 31,590 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $4.32M.
  • Barometer Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Barometer Capital Management's BioMarin Pharmaceuticals position peaked at $4.32M in Q2 2015.
  • 393 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Barometer Capital Management's 13F filing for Q3 2015, filed 30 Oct 2015.